Biogen Secures Subcutaneous Leqembi Approval: What It Means for Your ETF

Biogen has officially secured approval for a subcutaneous formulation of Leqembi, specifically designated for the initiation dose of the Alzheimer's therapy. This regulatory development marks a pivotal shift in the administration of the drug, potentially…